
Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
Author(s) -
Mohamad Moussa,
Athanasios Papatsoris,
Mohamad Abou Chakra,
Athanasios Dellis
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s240854
Subject(s) - urothelial cancer , urothelial carcinoma , metastatic urothelial carcinoma , medicine , oncology , anticancer drug , safety profile , cancer , drug , cancer research , adverse effect , bladder cancer , pharmacology